Journal of Clinical Oncology, Vol 16, 427-433, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator

OA Ogunbiyi, PJ Goodfellow, K Herfarth, G Gagliardi, PE Swanson, EH Birnbaum, TE Read, JW Fleshman, IJ Kodner and JF Moley
Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.

PURPOSE: Recent studies suggest that allelic loss of sequences from the long arm of chromosome 18 may be a useful prognostic indicator in colorectal cancer. The aim of the present study was to confirm whether 18q loss of heterozygosity (LOH) is of prognostic value in patients with colon cancer. METHODS: Genomic DNA was prepared from archival tumor and corresponding normal tissue specimens from 151 patients who had undergone potentially curative surgery for adenocarcinoma of the colon. Polymerase chain reaction (PCR) was used to assess allelic loss of five chromosome 18q microsatellite markers in the tumors. The relationship between allelic loss and disease-free and disease-specific survival was investigated. RESULTS: LOH was detected in 67 of 126 tumors. Chromosome 18q allelic loss was a negative prognostic indicator of both disease-free (relative risk [RR], 1.65; P = .01) and disease- specific survival (RR, 2.0; P = .003). 18q loss was also associated with significantly reduced disease-free and disease-specific survival in patients with stage II (P = .05 and P = .0156) and III (P = .038 and P = .032) disease. CONCLUSION: Chromosome 18q allelic loss is a prognostic marker in colorectal cancers. Chromosome 18 LOH studies may be useful in identifying patients with stage II disease who are at high risk for recurrence, and as such might benefit from adjuvant chemotherapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H.-J. Lenz Established Biomarkers for Colon Cancer ASCO Educational Book, January 1, 2009; 2009(1): 215 - 219. [Abstract] [Full Text] [PDF]

				Y. Jiang, G. Casey, I. C. Lavery, Y. Zhang, D. Talantov, M. Martin-McGreevy, M. Skacel, E. Manilich, A. Mazumder, D. Atkins, et al. Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer J. Mol. Diagn., July 1, 2008; 10(4): 346 - 354. [Abstract] [Full Text] [PDF]

				G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327. [Abstract] [Full Text] [PDF]

				H. Ji, J. Kumm, M. Zhang, K. Farnam, K. Salari, M. Faham, J. M. Ford, and R. W. Davis Molecular Inversion Probe Analysis of Gene Copy Alterations Reveals Distinct Categories of Colorectal Carcinoma Cancer Res., August 15, 2006; 66(16): 7910 - 7919. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. Kanazawa, Y. Kazama, J. Tanaka, T. Tanaka, S. Ishihara, and H. Nagawa SMAD4 Levels and Allelic Imbalance in 18q21 in Colorectal Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1654 - 1654. [Full Text] [PDF]

				D. Arango, P. Alhopuro, and L. A. Aaltonen Reply to the Letter to the Editor by Watanabe et al. Clin. Cancer Res., March 1, 2006; 12(5): 1654 - 1655. [Full Text] [PDF]

				H. Orita, N. Sakamoto, Y. Ajioka, T. Terai, O. Hino, N. Sato, T. Shimoda, T. Kamano, M. Tsurumaru, and H. Fujii Allelic loss analysis of early-stage flat-type colorectal tumors Ann. Onc., January 1, 2006; 17(1): 43 - 49. [Abstract] [Full Text] [PDF]

				N. Erill, A. Colomer, M. Calvo, A. Vidal, R. Roman, M. Verdu, C. Cordon-Cardo, and X. Puig A Novel Multiplexing, Polymerase Chain Reaction-Based Assay for the Analysis of Chromosome 18q Status in Colorectal Cancer J. Mol. Diagn., October 1, 2005; 7(4): 478 - 485. [Abstract] [Full Text] [PDF]

				P. Alhopuro, H. Alazzouzi, H. Sammalkorpi, V. Davalos, R. Salovaara, A. Hemminki, H. Jarvinen, J.-P. Mecklin, S. Schwartz Jr., L. A. Aaltonen, et al. SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6311 - 6316. [Abstract] [Full Text] [PDF]

				H. Alazzouzi, P. Alhopuro, R. Salovaara, H. Sammalkorpi, H. Jarvinen, J.-P. Mecklin, A. Hemminki, S. Schwartz Jr., L. A. Aaltonen, and D. Arango SMAD4 as a Prognostic Marker in Colorectal Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2606 - 2611. [Abstract] [Full Text] [PDF]

				C. Aschele, D. Debernardis, S. Lonardi, R. Bandelloni, S. Casazza, S. Monfardini, and L. Gallo Deleted in Colon Cancer Protein Expression in Colorectal Cancer Metastases: A Major Predictor of Survival in Patients With Unresectable Metastatic Disease Receiving Palliative Fluorouracil-Based Chemotherapy J. Clin. Oncol., September 15, 2004; 22(18): 3758 - 3765. [Abstract] [Full Text] [PDF]

				A. Zaniboni and R. Labianca Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann. Onc., September 1, 2004; 15(9): 1310 - 1318. [Abstract] [Full Text] [PDF]

				P. Mehlen and E. R. Fearon Role of the Dependence Receptor DCC in Colorectal Cancer Pathogenesis J. Clin. Oncol., August 15, 2004; 22(16): 3420 - 3428. [Abstract] [Full Text] [PDF]

				Y. Wang, T. Jatkoe, Y. Zhang, M. G. Mutch, D. Talantov, J. Jiang, H. L. McLeod, and D. Atkins Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1564 - 1571. [Abstract] [Full Text] [PDF]

				F. Graziano and S. Cascinu Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Onc., July 1, 2003; 14(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				C. B. Diep, L. Thorstensen, G. I. Meling, E. Skovlund, T. O. Rognum, and R. A. Lothe Genetic Tumor Markers With Prognostic Impact in Dukes' Stages B and C Colorectal Cancer Patients J. Clin. Oncol., March 1, 2003; 21(5): 820 - 829. [Abstract] [Full Text] [PDF]

				R S Houlston What we could do now: molecular pathology of colorectal cancer Mol. Pathol., August 1, 2001; 54(4): 206 - 214. [Abstract] [Full Text] [PDF]

				T. Watanabe, T.-T. Wu, P. J. Catalano, T. Ueki, R. Satriano, D. G. Haller, A. B. Benson, and S. R. Hamilton Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer N. Engl. J. Med., April 19, 2001; 344(16): 1196 - 1206. [Abstract] [Full Text] [PDF]

				K. C. Halling, A. J. French, S. K. McDonnell, L. J. Burgart, D. J. Schaid, B. J. Peterson, L. Moon-Tasson, M. R. Mahoney, D. J. Sargent, M. J. O'Connell, et al. Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers J Natl Cancer Inst, August 4, 1999; 91(15): 1295 - 1303. [Abstract] [Full Text] [PDF]